1 NAME OF THE MEDICINE
Sotalol hydrochloride

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each CARDOL tablet contains sotalol hydrochloride 160 mg as the active ingredient.

Excipients with known effect: trace quantities of sulfites.

For the full list of excipients, see Section 6.1 LIST OF EXCIPIENTS.

3 PHARMACEUTICAL FORM
CARDOL 160 mg tablet: 9.5mm, flat bevel edged, white tablet debossed 'SL' breakline '160' on one side and 'alpha symbol' on the other.

4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Prevention and treatment of supraventricular and ventricular arrhythmias.

4.2 DOSE AND METHOD OF ADMINISTRATION
Sotalol is used orally for the prevention and treatment of arrhythmias.

As with other antiarrhythmic agents, sotalol should be initiated and doses increased in a facility capable of monitoring and assessing cardiac rhythm. The dosage must be individualised for each patient on the basis of therapeutic response and tolerance. Proarrhythmic events can occur not only at commencement of therapy, but also with each upward dosage adjustment.

Sotalol should be taken preferably 1 to 2 hours before meals.

Oral dosage of sotalol should be adjusted gradually allowing 2 to 3 days between dosing increments in order to attain steady-state, and to allow monitoring of QT intervals. Graded dose adjustment will help prevent the use of doses which are higher than necessary to control the arrhythmia. The recommended initial oral dosing schedule is 160 mg/day, given in two divided doses at approximately 12 hour intervals. This dose may be increased, if necessary, after appropriate evaluation to 240 or 320 mg/day. In most patients, a therapeutic response is obtained at a total daily dose of 160 to 320 mg/day, given in 2 divided doses. Some patients with life-threatening refractory ventricular arrhythmias may require doses as high as 480 to 640 mg/day; however, these doses should only be prescribed when the potential benefit outweighs the increased risk of adverse events particularly proarrhythmias.

Because of the long elimination half-life of sotalol, dosing on more than a twice daily regimen is not usually necessary.

**With Impaired Renal Function**
As sotalol is primarily excreted by the kidneys, a dosage adjustment should be made.
4.3 CONTRAINDICATIONS

Bronchospasm (e.g. bronchial asthma or chronic obstructive airway disease)

Allergic disorders (including allergic rhinitis) which may suggest a predisposition to bronchospasm

Right ventricular failure secondary to pulmonary hypertension

Significant right ventricular hypertrophy

Sinus bradycardia (less than 45 to 50 beats/minute)

Second and third degree A-V block or sick sinus syndrome unless a functioning pacemaker is present

Shock (including cardiogenic and hypovolaemic shock)

Uncontrolled congestive heart failure

Severe renal impairment (creatinine clearance <10 mL/min)

Congenital or acquired long QT syndromes

Hypersensitivity to sotalol hydrochloride, other beta blockers or the excipients

Anaesthesia that produces myocardial depression

Severe sinus node dysfunction

Sinoatrial block

Hypomagnesaemia

Hypotension

Late stages of peripheral arterial occlusive disease

Metabolic acidosis

Torsades de pointes

Raynaud’s phenomenon and severe peripheral circulatory disturbance

Untreated phaeochromocytoma

Intravenous administration of verapamil or diltiazem calcium antagonists or other anti-arrhythmic agents (such as disopyramide) is contraindicated in patients treated with sotalol hydrochloride (except in the case of intensive care medicine).

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Patients with supraventricular or asymptomatic ventricular arrhythmias.

No antiarrhythmic drug has been shown to decrease the incidence of sudden death in patients with supraventricular or asymptomatic ventricular arrhythmias. Since most antiarrhythmic drugs have the potential to cause proarrhythmias or increase the incidence of sudden death, physicians should carefully consider the risks and benefits of antiarrhythmic therapy in these patients.

Mortality:
Post-myocardial infarction patients with asymptomatic ventricular arrhythmias showed a significant increase in mortality and in non-fatal cardiac arrest rate in patients treated with encainide or flecainide compared with a matched placebo-treated group. The Cardiac Arrhythmia Suppression Trial (CAST) was continued using a revised protocol with the moricizine and placebo arms only. The trial was prematurely terminated because of a trend towards an increase in mortality in the moricizine treated group. The applicability of these results to other populations or other antiarrhythmic agents is uncertain, but at present it is prudent to consider these results when using any antiarrhythmic agent.

**Proarrhythmia**

**Post-Marketing Experience.** The most dangerous adverse effect of antiarrhythmic agents is the aggravation of pre-existing arrhythmias or the provocation of new arrhythmias. Agents that prolong the QT interval may cause *Torsade de Pointes*, a polymorphic ventricular tachycardia associated with prolongation of the QT interval. Experience to date indicates that the risk of *Torsade de Pointes* is associated with the prolongation of the QT interval, reduction in heart rate, reduction in serum potassium and magnesium (e.g. as a consequence of diuretic use), high plasma drug concentrations (e.g. as a consequence of overdosage or renal insufficiency), and with the concomitant use of sotalol and other medication such as antidepressants and Class I antiarrhythmics which have been associated with *Torsade de Pointes*. Females appear to be at increased risk of developing *Torsade de Pointes*. ECG monitoring immediately prior to or following the episodes usually reveals a significantly prolonged QT interval and a significantly prolonged QTc interval. In clinical trials, sotalol generally has not been administered to patients whose pretreatment QTc interval exceeded 450 msec. Sotalol should be titrated very cautiously in patients with prolonged QT intervals.

*Torsade de Pointes* is dose dependent, usually occurs early after commencing therapy or increasing the dose, and terminates spontaneously in the majority of patients. Although most episodes of *torsade de pointes* are self-limited or associated with symptoms (e.g. syncope), they can progress to ventricular fibrillation.

**Clinical Studies for Arrhythmia.** During clinical trials, 4.3% of 3257 patients with arrhythmias experienced a new or worsened ventricular arrhythmia, including sustained ventricular tachycardia (approximately 1%) and *Torsade de Pointes* (2.4%). In addition, in approximately 1% of patients, deaths were considered possibly drug related. In patients with other, less serious, ventricular arrhythmias and supraventricular arrhythmias, the incidence of *Torsade de Pointes* was 1% and 1.4% respectively.

Serious proarrhythmias including *Torsade de Pointes* were dose related as indicated in Table 1 below:

<table>
<thead>
<tr>
<th>Daily Dose (mg)</th>
<th>Incidence of Serious Proarrhythmias</th>
<th>Patients (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-80</td>
<td>0%</td>
<td>(0/72)</td>
</tr>
<tr>
<td>81-160</td>
<td>0.5%</td>
<td>(4/838)</td>
</tr>
<tr>
<td>161-320</td>
<td>1.8%</td>
<td>(17/960)</td>
</tr>
<tr>
<td>321-480</td>
<td>4.5%</td>
<td>(21/471)</td>
</tr>
<tr>
<td>481-640</td>
<td>4.6%</td>
<td>(15/327)</td>
</tr>
<tr>
<td>&gt;640</td>
<td>6.8%</td>
<td>(7/103)</td>
</tr>
</tbody>
</table>

* Torsade de Pointes or New Sustained VT/VF

In clinical trials of patients with sustained VT/VF the incidence of severe proarrhythmia (torsades de pointes or new sustained VT/VF) was <2% at doses up to 320 mg. The incidence more than doubled at higher doses.

Other risk factors for *Torsade de Pointes* were excessive prolongation of the QTc and history of cardiomegaly or congestive heart failure. Patients with sustained ventricular tachycardia and a history of congestive heart failure have the highest risk of serious proarrhythmia (approximately 7%). Proarrhythmic events must be anticipated not only on initiating therapy, but with every upward dose adjustment; events tend to occur within 7 days of initiating therapy or with an increase in dose. Initiating therapy at 80 mg twice a day with gradual upward dose titration thereafter decreases the risk of proarrhythmia (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION). Sotalol should be used with caution if the QTc is greater than 500 msec on-therapy, and
serious consideration should be given to reducing the dose or discontinuing therapy when the QT interval exceeds 550 msec. Due to the multiple risk-factors associated with Torsade de Pointes, however, caution should be exercised regardless of the QTc interval.

Proarrhythmic events must be anticipated not only on initiating therapy, but with every upward dose adjustment. Proarrhythmic events most often occur within 7 days of initiating therapy or of an increase in dose; a large percentage of serious proarrhythmias (torsade de pointes and worsened VT) occurred within 7 days of initiating sotalol therapy, while the majority of such events occurred within 3 days of initiation or a dosage change. Initiating therapy at 80 mg BID with gradual upward dose titration and appropriate evaluations for efficacy (e.g. PES or Holter) and safety (e.g. QT interval, heart rate and electrolytes) prior to dose escalation, should reduce the risk of proarrhythmia. Avoiding excessive accumulation of sotalol in patients with diminished renal function, by appropriate dose reduction, should also reduce the risk of proarrhythmia (see Section 4.2 DOSE AND METHOD OF ADMINISTRATION).

**Congestive Heart Failure**

Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure (CHF), and Beta-blockade depresses myocardial contractility and may precipitate cardiac failure in some patients with a history of cardiac failure, chronic myocardial insufficiency or unsuspected cardiomyopathy. Moreover, patients with CHF have a higher risk of torsade de pointes (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Proarrhythmia). In patients without a history of cardiac failure, continuing depression of the myocardium may lead to cardiac failure. If cardiac failure persists, CARDOL should be withdrawn (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Abrupt Withdrawal).

In patients with controlled CHF, sotalol should be administered cautiously. The positive inotropic action of digitalis may be reduced when the two drugs are used concomitantly. Both digitalis and sotalol slow AV conduction. If cardiac failure continues despite adequate digitalisation, sotalol should be discontinued. In patients without a history of heart failure, continued depression of the myocardium over a period of time can, in some cases, lead to cardiac failure. At the first sign of impending heart failure, appropriate therapy must be established and consideration should be given to discontinuation of treatment with sotalol.

Caution is advised when initiating therapy in patients with left ventricular dysfunction controlled by therapy (i.e. ACE inhibitors, diuretics, digitalis, etc); a low initial dose and careful dose titration is appropriate.

(Note. Although congestive heart failure has been considered to be a contraindication to the use of beta-blockers, there is a growing literature on the experimental use of beta-adrenergic blocking drugs in heart failure. As further trials are needed to identify which patients are most likely to respond to which drugs, beta-blockers should not normally be prescribed for heart failure outside of specialist centres.)

**Conduction Disturbances**

Excessive prolongation of the QT interval (> 550 msec) can promote serious arrhythmias and should be avoided (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Proarrhythmia). Sinus bradycardia (heart rate less than 50 bpm) occurred in some patients receiving sotalol in clinical trials, and led to discontinuation in a small percentage of patients. Bradycardia itself increases the risk of torsade de pointes. Sinus pause, sinus arrest and sinus node dysfunction occur in less than 1% of patients. The incidence of 2nd- or 3rd-degree AV block is approximately 1%.

**Recent Myocardial Infarction**

In post-infarction patients with impaired left ventricular function, the risk versus benefit of sotalol administration must be considered. Careful monitoring and dose titration are critical during initiation and follow-up of treatment. The adverse results of clinical trials involving antiarrhythmic drugs (i.e. apparent increase in mortality) suggest that sotalol should be avoided in patients with left ventricular ejection fractions ≤ 40% without serious ventricular arrhythmias.

In a large controlled trial in patients with a recent myocardial infarction without heart failure, who did not necessarily have ventricular arrhythmias, oral sotalol hydrochloride therapy was associated with a non-statistically significant risk reduction in mortality compared to the placebo group (18%). In this post-infarction study using a fixed dose of 320 mg once a day and in a second small randomised trial in high-risk post-infarction
patients with left ventricular ejection fractions ≤ 40% treated with high doses (640 mg/day), there were suggestions of an excess of early sudden deaths.

**Abrupt Withdrawal**

Care should be taken if beta-blockers have to be withdrawn abruptly in patients with coronary artery disease. Hypersensitivity to catecholamines is observed in patients withdrawn from beta-blocker therapy. Severe exacerbation of angina pectoris and precipitation of myocardial infarction and ventricular arrhythmias have occurred following abrupt discontinuation of beta-blockade in patients with ischaemic heart disease. Therefore, it is recommended that the dosage be reduced gradually over a period of 8 to 14 days during which time the patient's progress should be assessed. Sotalol should be reinstituted temporarily if the angina worsens.

If the drug must be withdrawn abruptly in these patients, close observation is required since latent coronary insufficiency may be unmasked. In the peri-operative period, sotalol should not be withdrawn, unless indicated.

**Non-Allergic Bronchospasm (e.g. chronic bronchitis and emphysema)**

Patients with bronchospastic diseases should in general not receive beta-blockers. It is prudent, if sotalol is to be administered, to use the smallest effective dose, so that inhibition of bronchodilation produced by endogenous or exogenous catecholamine stimulation of beta-2 receptors may be minimised.

**Sick Sinus Syndrome**

Sotalol should be used only with extreme caution in patients with sick sinus syndrome associated with symptomatic arrhythmias, because it may cause sinus bradycardia, sinus pauses or sinus arrest.

**Concomitant therapy with Calcium Channel Blocking Drugs**

Concomitant use of beta-blockers and calcium channel blockers has resulted in hypotension, bradycardia, conduction defects and cardiac failure. Beta-blocking agents should be avoided in combination with cardiodepressant calcium-channel blockers because of the additive effect on atrioventricular conduction and ventricular function.

**Peripheral Circulation**

Beta-blockade may impair the peripheral circulation and exacerbate the symptoms of peripheral vascular disease, especially at the start of treatment.

**Antiarrhythmic Drugs**

Interactions have been reported during concomitant beta-blocker therapy with the Class IA agents disopyramide, and less frequently quinidine; Class IB agents, tocainide, mexiletine and lidocaine (lignocaine); Class IC agents, flecainide and propafenone (not available in Australia); the Class III agent, amiodarone; and the Class IV antiarrhythmic agents. Concomitant use of sotalol with these agents, and with other beta-blocking drugs is not recommended.

**Prinzmetal Angina**

There is a risk of exacerbating coronary artery spasm if patients with Prinzmetal or variant angina are treated with a beta-blocker. If this treatment is essential, it should only be undertaken in a Coronary or Intensive Care Unit.

**Euthyroid Hyperthyroxinaemia**

The effects of beta-blockers on thyroid hormone metabolism may result in elevations of serum free thyroxine (T4) levels. In the absence of any signs or symptoms of hyperthyroidism, additional investigation is necessary before a diagnosis of thyrotoxicosis can be made.

**Anaphylaxis**

Sotalol’s beta-blocking properties may elevate the patient's sensitivity to allergens and exacerbate the severity of anaphylactic reactions. There may be increased difficulty in treating an allergic type reaction in patients on beta-blockers. Patients with a history of severe hypersensitivity reactions and patients who are currently undergoing
desensitisation therapy are at higher risk of developing severe anaphylactic reactions. Sotalol should therefore only be administered to such patients if absolutely indicated. Patients with a history of anaphylactic reaction to a variety of allergens may have a more severe reaction on repeated challenge while taking beta-blocking agents. Such patients may be unresponsive to the usual doses of adrenaline (epinephrine) used to treat the allergic reaction. Adrenaline (epinephrine) should be administered with caution since it may not have its usual effects in the treatment of anaphylaxis. On the one hand, larger doses of Adrenaline (epinephrine) may be needed to overcome the bronchospasm, while on the other hand, these doses can be associated with excessive alpha adrenergic stimulation with consequent hypertension, reflex bradycardia, and heart block and possible potentiation of bronchospasm. Alternatives to the use of large doses of Adrenaline (epinephrine) include vigorous supportive care such as fluids and the use of beta agonists including parenteral salbutamol or isoproterenol to overcome bronchospasm and norepinephrine to overcome hypotension.

Anaesthesia and the Peri-Operative Period

Beta-blockade may have beneficial effects in decreasing the incidence of arrhythmias and myocardial ischaemia during anaesthesia and the post-operative period. It is currently recommended that maintenance beta-blockade be continued peri-operatively. The anaesthetist must be made aware of beta-blockade because of the potential for interactions with other drugs, resulting in severe bradyarrhythmias and hypotension, the decreased reflex ability to compensate for blood loss, hypovolaemia and regional sympathetic blockade, and the increased propensity for vagal-induced bradycardia. Incidents of protracted severe hypotension or difficulty restoring normal cardiac rhythm during anaesthesia have been reported.

Modern inhalational anaesthetic agents are generally well tolerated, although older agents (ether, cyclopropane, methoxyflurane, trichloroethylene) were sometimes associated with severe circulatory depression in the presence of beta-blockade.

Diabetes

Beta-blockers affect glucose metabolism and may mask some important premonitory signs of acute hypoglycaemia, such as tachycardia.

In patients with insulin or non-insulin dependent diabetes, especially labile diabetes, or with a history of spontaneous hypoglycaemia, beta-blockade may result in the loss of diabetic control and delayed recovery from hypoglycaemia. The dose of insulin or oral hypoglycaemic agent may need adjustment.

Monitoring is recommended in patients on strict fasts and diabetics whose blood sugar levels are subject to major fluctuations (masking of hypoglycaemic states).

Patients initiating treatment require close cardiac monitoring for ventricular arrhythmia in the titration phase of antiarrhythmic therapy and should only be started on the drug if emergency resuscitation equipment is available and if the possibility of monitoring is assured. Regular check ups are necessary during treatment.

Thyrotoxicosis

Beta-blockade may mask certain clinical signs of hyperthyroidism (e.g. tachycardia). Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-blockade which might be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm.

Other Metabolic Effects

Beta-adrenoreceptors are involved in the regulation of lipid as well as carbohydrate metabolism. Some drugs affect the lipid profile adversely, although the long-term clinical significance of this change is unknown and the effect appears to be less for drugs with intrinsic sympathomimetic activity.

Use of Catecholamine-Depleting Agents

Concomitant use of drugs such as reserpine and guanethidine requires careful monitoring since the added effect of a beta-blocker may produce an excessive reduction of the resting sympathetic nervous tone.
Clonidine
Concurrent use of beta-blockers and clonidine should be avoided because of the risk of adverse interaction and severe withdrawal symptoms. If administered concomitantly, the clonidine should not be discontinued until several days after the withdrawal of the beta-blocker.

Phaeochromocytoma
In patients with this condition, an alpha-blocking drug (e.g. phentolamine/ phenoxybenzamine) should be administered before the beta-blocker to avoid exacerbation of hypertension.

Eye and Skin Reactions
Various skin rashes and conjunctival xerosis have been reported with beta-blockers. Cross-reactions may occur between beta-blockers, therefore substitutions within the group may not necessarily preclude occurrence of symptoms.

Allergic Conditions
These may be exaggerated by beta-blockade (e.g. allergic rhinitis during the pollen season and allergic reactions to honey bee and wasp stings). Beta-blockers should be avoided if there is a risk of bronchospasm.

Hyperthyroidism
Because beta-blockers may mask the clinical signs of developing or continuing hyperthyroidism, resulting in symptomatic improvement without any change in thyroid hormone status, special care should be exercised in those patients who are hyperthyroid and are also receiving beta-blockers.

Abrupt withdrawal of beta-blockade in hyperthyroid patients may be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm, and should be avoided in these patients.

Electrocardiographic Monitoring
Regular electrocardiographic monitoring should be carried out during sotalol therapy because of prolongation of the QT interval (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Proarrhythmia, Post-Marketing Experience). Excessive prolongation of the QT interval, >550 msec, can be a sign of toxicity and should be avoided. Sinus bradycardia (heart rate <50 bpm) occurred at a frequency of 13% in arrhythmia patients receiving sotalol in clinical trials. Bradycardia itself increases the rate of Torsade de Pointes. Sinus pause, sinus arrest and sinus node dysfunction occur in less than 1% of patients. The incidence of 2nd or 3rd degree AV block is approximately 1%.

Electrolyte Disturbances
Sotalol should not be used in patients with hypokalaemia or hypomagnesaemia prior to correction of imbalance; these conditions can exaggerate the degree of QT prolongation and increase the potential for torsades de pointes. Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhoea or patients receiving concomitant magnesium- and/or potassium-depleting drugs.

Before initiating sotalol therapy, serum electrolytes should be obtained and any electrolyte imbalance corrected. It is important to monitor electrolyte balance at regular intervals and correct any imbalance throughout therapy. When significant diarrhoea or other intercurrent illness associated with electrolyte losses occurs during treatment with sotalol patients should be instructed to contact their doctors so that they can be closely monitored with frequent checks of plasma electrolytes and receive replacement therapy as appropriate (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Proarrhythmia, Post-Marketing Experience).

Excessive Bradycardia
If excessive bradycardia occurs alone or with hypotension, atropine 0.5 to 2 mg should be given intravenously and immediately followed, if necessary, by a beta-receptor stimulating agent such as isoprenaline (see Section 4.9 OVERDOSE).

Patients experiencing this effect on initial administration of sotalol should be removed temporarily from therapy. Sotalol may be reintroduced later at a lower dosage level.
A reduction in dosage by 80 or 160 mg/day may be advisable to alleviate symptoms of weakness and dizziness in cases where the blood pressure continues to fall after a month or two of sotalol administration.

**Psoriasis**

Beta-blockers have been reported rarely to exacerbate the symptoms of psoriasis vulgaris.

**Use in Hepatic Impairment**

Since sotalol is not subject to first-pass metabolism, patients with hepatic impairment show no alteration in clearance of sotalol.

**Use in Renal Impairment**

In patients with severe renal disease, haemodynamic changes following beta-blockade may impair renal function further. Beta-blockers which are excreted mainly by the kidney may require dose adjustment in patients with renal impairment. Sotalol excretion is reduced in patients with renal impairment. Dosage should therefore be adjusted accordingly. Sotalol is contraindicated in patients with severe renal impairment (creatinine clearance <10 mL/min).

**Use in the Elderly**

No data available.

**Paediatric Use**

The safety and effectiveness of sotalol in children under 18 has not been established.

**Effects on Laboratory Tests**

The presence of sotalol in the urine may result in falsely elevated levels of urinary metanephrine when measured by photometric methods. Patients suspected of having phaeochromocytoma and who are treated with sotalol should have their urine screened utilising the high performance liquid chromatographic assay with solid phase extraction.

**4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS**

**Alcohol**

The plasma clearance of sotalol is reduced after alcohol ingestion.

**Insulin and Oral Hypoglycaemics**

Beta-blocking drugs may prolong the hypoglycaemic action of these drugs especially in conditions where glucose mobilisation may be compromised, e.g. labile diabetes, diabetic ketoacidosis and fasting diabetic patients. Symptoms of hypoglycaemia may be masked by sotalol. Hyperglycaemia may occur, and the dosage of antidiabetic drugs may require adjustment (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Diabetes).

**Anaesthetics**

Agents such as ether, chloroform and cyclopropane are contraindicated with sotalol (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Anaesthesia and the Peri-Operative Period).

**Beta-2 Receptor Stimulants**

Patients in need of beta-agonists should not normally receive sotalol. However, if concomitant therapy is necessary beta-agonists such as salbutamol, terbutaline and isoprenaline may have to be administered in increased dosages.

**Calcium Channel Blocking Drugs**

Concomitant use of beta-blocking drugs and calcium channel blockers has resulted in hypotension, bradycardia, conduction defects and cardiac failure. Beta-blockers should be avoided in combination with cardiodepressant
calcium-channel blocking agents such as verapamil and diltiazem because of the additive effects on atrioventricular conduction and ventricular function (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Concomitant therapy with Calcium Channel Blocking Drugs).

Catecholamine-Depleting Agents
Concurrent use of catecholamine-depleting drugs, such as reserpine and guanethidine, with a beta-blocking agent may produce an excessive reduction of resting sympathetic nervous tone. Patients should be closely monitored for evidence of hypotension and/or marked bradycardia which may produce syncope.

Noradrenaline, Clonidine and MAO inhibitors
An antagonistic effect between noradrenaline or MAO inhibitors or abrupt discontinuation of concomitant clonidine and sotalol has been observed. Concurrent administration of clonidine and sotalol has caused increased blood pressure compared with clonidine or sotalol alone. The combination of beta-adrenoreceptor antagonists and clonidine should be avoided (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Clonidine). Beta-blocking drugs may potentiate the rebound hypertension sometimes observed after discontinuation of clonidine; therefore, the beta-blocker should be discontinued slowly several days before the gradual withdrawal of clonidine.

Drugs Prolonging the QT interval
Drugs known to prolong the QT interval and/or to be associated with atypical ventricular tachycardia (AVT, Torsade de Pointes) especially phenothiazines, quinidine, disopyramide and tricyclic antidepressants, terfenadine, astemizole and certain quinolone antibiotics (e.g. sparfloxacin) macrolide antibiotics (erythromycin), probucol, haloperidol, halofantrine or terodiline should be avoided (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Proarrhythmia, Post-Marketing Experience).

Other drugs that have been associated with an increased risk for torsades de pointes include erythromycin IV, halofantrine, pentamidine, and quinolone antibiotics. Patients may experience an excessive drop in blood pressure with concomitant use of sotalol hydrochloride and tricyclic antidepressants, barbiturates, phenothiazines, opioids, anti hypertensives, diuretics or vasodilator.

Antiarrhythmic Agents
Interactions have been reported during concomitant use of beta-blockers with the Class IA agents disopyramide, and less frequently quinidine; Class IB agents, tocainide, mexiletine and lidocaine (lignocaine); Class IC agents, flecaainide and propafenone (not available in Australia); the Class III agent, amiodarone; and the Class IV antiarrhythmic agents. Concomitant sotalol therapy with these drugs, and with other beta-blocking agents is not recommended. The concomitant use of other beta-blocking agents with sotalol may result in additive Class II effects.

Potassium-Depleting Diuretics
Hypokalaemia or hypomagnesaemia may occur, increasing the potential for Torsade de Pointes (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Electrolyte Disturbances).

Other potassium-depleting drugs
Amphotericin B (IV route), corticosteroids (systemic administration), and some laxatives may also be associated with hypokalaemia; potassium levels should be monitored and corrected appropriately during concomitant administration with sotalol.

Digoxin
Single and multiple doses of sotalol do not significantly affect serum digoxin levels. Proarrhythmic events were more common in patients treated with sotalol who are also receiving digoxin; however, this may be related to the presence of congestive heart failure, a known risk factor for proarrhythmia, in the patient treated with digoxin. Association of digitalis glycosides with beta-blockers may increase auriculo-ventricular conduction time.
Floctafenine
Beta-adrenergic blocking agents may impede the compensatory cardiovascular reactions associated with hypotension or shock that may be induced by Floctafenine.

Neuromuscular blocking agents like Tubocurarin
The neuromuscular blockade is prolonged by beta-blocking agents.

Insulin and oral hypoglycemics
Hypoglycemia and hyperglycemia may occur and the dosage of antidiabetic drug should be adjusted accordingly (See Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Diabetes).

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on Fertility
No data available.

Use in Pregnancy
Pregnancy Category: C
Beta-adrenergic blocking agents may cause bradycardia in the foetus and newborn infant. Sotalol has been shown to cross the placental barrier and cause bradycardia or hypoglycaemia in the newborn.

During the late stages of pregnancy these drugs should only be given after weighing the needs of the mother against the risk to the foetus. The neonate should be monitored very carefully for 48 – 72 hours after delivery if it was not possible to interrupt maternal therapy with sotalol 2-3 days before the birthdate.

Use in Lactation
Sotalol is actively excreted in breast milk (milk:plasma ratio = 5.4:1) and therefore should not be administered to nursing mothers.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

This drug may affect the individual's ability to drive a vehicle, operate machinery or work safely under precarious conditions. This applies particularly at the beginning of treatment, on increasing the dose or when switching to another medication as well as when alcohol is consumed simultaneously.

Patients should be warned about the potential for dizziness and advised not to drive or operate machinery if these symptoms occur or until their individual susceptibility is known.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Sotalol is well tolerated in the majority of patients, with the most frequent adverse events arising from its beta-blockade properties. Adverse events are usually transient in nature and rarely necessitate interruption of, or withdrawal from, treatment. These include dyspnœa, fatigue, dizziness, headache, fever, excessive bradycardia and/or hypotension. If they do occur, these side effects usually disappear when the dosage is lowered. The most significant adverse events, however, are those due to proarrhythmia, including Torsade de Pointes.

Frequency is defined using the following convention: very common (≥ 1/10); common (≥ 1/100, <1/10); uncommon (≥1/1,000, < 1/100); rare (≥ 1/10,000, < 1/1,000); very rare (< 1/10,000) including isolated reports. The following are adverse events considered related to therapy with Sotalol:

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Common</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac disorders</td>
<td>Ventricular tachyarrhythmias</td>
<td>Congestive heart failure, Increased ventricular ectopic beat frequency, cardiogenic shock and AV block (I) have been observed after intravenous administration.</td>
</tr>
<tr>
<td></td>
<td>Torsade de pointes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chest pain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Exacerbation of heart failure</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bradycardia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hypotension</td>
<td></td>
</tr>
<tr>
<td>Cold extremities</td>
<td>Cold extremities</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>Dyspnoea</td>
<td></td>
</tr>
<tr>
<td>Palpitations</td>
<td>Palpitations</td>
<td></td>
</tr>
<tr>
<td>Oedema</td>
<td>Oedema</td>
<td></td>
</tr>
<tr>
<td>ECG abnormalities</td>
<td>ECG abnormalities</td>
<td></td>
</tr>
<tr>
<td>AV conduction disorder</td>
<td>AV conduction disorder</td>
<td></td>
</tr>
<tr>
<td>Ventricular tachycardia</td>
<td>Ventricular tachycardia</td>
<td></td>
</tr>
<tr>
<td>Exacerbation in angina pectoris</td>
<td>Exacerbation in angina pectoris</td>
<td></td>
</tr>
<tr>
<td>Prolonged QT interval</td>
<td>Prolonged QT interval</td>
<td></td>
</tr>
<tr>
<td>Proarrhythmia</td>
<td>Proarrhythmia</td>
<td></td>
</tr>
<tr>
<td>Syncope</td>
<td>Syncope</td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>Heart failure</td>
<td></td>
</tr>
<tr>
<td>presyncope.</td>
<td>presyncope.</td>
<td></td>
</tr>
<tr>
<td>Hypotension and bradycardia are more frequent after intravenous administration</td>
<td>Hypotension and bradycardia are more frequent after intravenous administration</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vascular disorders</th>
<th>Exacerbation of peripheral occlusive disease, cold limbs (cold extremities)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vasodilation AICD discharge</td>
</tr>
<tr>
<td></td>
<td>Hypertension</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Haematologic disorders</th>
<th>Bleeding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biochemical abnormalities</td>
<td>Changes in plasma lipid concentrations</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Skin and subcutaneous tissue disorder</th>
<th>Rash</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Skin reactions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Alopecia</th>
<th>Hyperhidrosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drugs with beta-blocking activity may trigger psoriasis, exacerbate this condition or give rise to psoriatic exanthema</td>
<td></td>
</tr>
<tr>
<td>Cutaneous thickening</td>
<td></td>
</tr>
<tr>
<td>Pruritus</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gastrointestinal disorder</th>
<th>Diarrhoea</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Nausea/vomiting</td>
</tr>
<tr>
<td></td>
<td>Flatulence</td>
</tr>
<tr>
<td></td>
<td>Dyspepsia</td>
</tr>
<tr>
<td></td>
<td>Abdominal pain</td>
</tr>
<tr>
<td></td>
<td>Colon problems</td>
</tr>
</tbody>
</table>

| Dry mouth |

<table>
<thead>
<tr>
<th>Musculoskeletal, connective tissue and bone disorders</th>
<th>Muscle spasms</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cramps</td>
</tr>
<tr>
<td></td>
<td>Extremity pain</td>
</tr>
<tr>
<td></td>
<td>Back pain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dizziness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drowsiness</td>
</tr>
<tr>
<td>Lethargy</td>
</tr>
<tr>
<td>Fatigue</td>
</tr>
<tr>
<td>Asthenia</td>
</tr>
<tr>
<td>Weakness</td>
</tr>
<tr>
<td>Vertigo</td>
</tr>
<tr>
<td>Lightheadedness</td>
</tr>
<tr>
<td>Headache</td>
</tr>
<tr>
<td>Sleep disturbances</td>
</tr>
<tr>
<td>Paraesthesia</td>
</tr>
<tr>
<td>Dysgeusia</td>
</tr>
<tr>
<td>Perspiration</td>
</tr>
<tr>
<td>Altered consciousness</td>
</tr>
<tr>
<td>Paresthesia</td>
</tr>
<tr>
<td>Stroke</td>
</tr>
</tbody>
</table>
Psychiatric disorders | Sleep disorder  
| Depression  
| Mood changes  
| Anxiety  
| Appetite disorder  

Reproductive system and breast disorders | Sexual dysfunction  
| Impotence  

Respiratory disorders | Pulmonary problem  
| Upper respiratory tract problem  
| Asthma  

Metabolic disorder | Abnormal lab value  
| Weight change  

Eye disorders | Visual disturbances (including eye irritation, deterioration of eyesight, blurred vision, photophobia)  

Ear and labyrinth disorders | Hearing disturbances  

General disorders and administration site conditions | Pyrexia  
| Taste abnormalities  
| Shortness of breath  
| Exacerbation of weakness  
| Oedema  
| Dyspnoea  
| Infection  
| Localised pain  

Retroperitoneal fibrosis  
Facial atrophy  

In clinical trials, 3256 patients with cardiac arrhythmias (1363 with sustained ventricular tachycardia) received oral sotalol, of whom 2451 received the drug for at least two weeks. The most significant adverse events were *Torsade de Pointes* and other serious new ventricular arrhythmias (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Proarrhythmia, Post-Marketing Experience), which occurred at the following rates outlined in Table 2:

**Table 2. Percentage incidence of *torsades de pointes* and sustained ventricular tachycardia/fibrillation**

<table>
<thead>
<tr>
<th>Patient Population</th>
<th>VT/VF (n=1363)</th>
<th>NSVT/PVC (n=946)</th>
<th>SVA (n=947)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Torsade de Pointes</td>
<td>4.1%</td>
<td>1.0%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Sustained VT/VF</td>
<td>1.2%</td>
<td>0.7%</td>
<td>0.3%</td>
</tr>
</tbody>
</table>

VT = ventricular tachycardia  
VF = ventricular fibrillation  
NSVT = nonsustained ventricular tachycardia  
PVC = premature ventricular contraction  
SVA = supraventricular arrhythmia  

Overall, discontinuation of sotalol due to unacceptable adverse events was necessary in 18% of all patients in cardiac arrhythmia trials. The most common adverse events leading to discontinuation of sotalol were: fatigue 4%, bradycardia (<50 bpm) 3%, dyspnoea 3%, proarrhythmia 2%, asthenia 2% and dizziness 2%.

**Less Common Reactions <1%**

**Biochemical Abnormalities.** Changes in antinuclear factor (ANF) titres have been reported but the clinical significance of this is not clear.
**Cardiovascular.** Congestive heart failure, prolonged QT interval. Increased ventricular ectopic beat frequency, cardiogenic shock and AV block (I) have been observed after intravenous administration.

**Dermatological.** Cutaneous thickening, pruritus.

**Psychiatric.** Unusual dreams.

**Others.** Retroperitoneal fibrosis, facial atrophy.

**Serious or Life-Threatening Reactions.**

Myocardial insufficiency may require treatment with digitalis and diuretics. Bradycardia may respond to atropine (see Section 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE - Excessive Bradycardia). Bronchospasm may be reversed with a beta-2 stimulant. Hypotension, if severe, may require use of a vasopressor. Cardiac infarction following too abrupt a withdrawal of the beta-blocker from patients with ischaemic heart disease can be avoided by gradual reduction of dose. Temporary overdrive pacing is suggested as treatment of ventricular arrhythmias in association with prolonged QT interval.

**Not known:** (Frequency cannot be estimated on the basis of available data)

**Blood and lymphatic system disorders.** Thrombocytopenia

**Skin and subcutaneous tissue disorders.** Alopecia, hyperhidrosis.

**Other potential adverse effects.**

Marketing experience with sotalol hydrochloride shows an adverse experience profile similar to that described above from clinical trials. Voluntary reports since introduction include rare reports (less than one report per 10,000 patients) of: emotional lability, slightly clouded sensorium, in coordination, vertigo, paralysis, thrombocytopenia, eosinophilia, leukopenia, photosensitivity reaction, fever, pulmonary oedema, hyperlipidaemia, myalgia, pruritus, reversible alopecia.

**Additional adverse effects have been reported with other beta-adrenergic blocking agents.**

**Central Nervous System.** Reversible mental depression progressing to catatonia; and acute reversible syndrome characterised by disorientation for time and place, short-term memory loss and decreased performance on neuropsychometrics.

**Allergic.** Fever, combined with aching and sore throat, laryngospasm, respiratory distress.

**Hematologic.** Agranulocytosis; thrombocytopenic or nonthrombocytopenic purpura.

**Gastrointestinal.** Mesenteric arterial thrombosis; ischemic colitis.

**Other.** Peyronie's disease, Raynaud's phenomenon.

**Reporting Suspected Adverse Effects**

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

### 4.9 OVERDOSE

**Symptoms**

Several cases, one fatal, of sotalol intoxication have been reported. Clinical features include: asystole, severe bradycardia, congestive heart failure, hypotension, prolongation of QT interval, premature ventricular complexes, ventricular tachyarrhythmias, *Torsade de Pointes*, hypoglycaemia and bronchospasm.
Treatment

Close monitoring of the electrocardiogram in patients with suspected sotalol intoxication is recommended. Every effort should be made to correct, promptly, metabolic and electrolyte imbalances which might contribute to the initiation of ventricular arrhythmias.

Gastric lavage, and activated charcoal should be administered when an overdose of sotalol tablets is suspected. Bradycardia and hypotension should be corrected prior to gastric lavage or endotracheal intubation as these procedures may increase vagal tone.

Depending on the symptoms, the following therapeutic measures are suggested:

**Severe Bradycardia.** Atropine 1 to 2 mg intravenously may be used to induce vagal blockade. If bradycardia persists, intravenous isoprenaline may be given. An appropriate regime would be 5 micrograms bolus, followed by an infusion of 0.5 to 10 micrograms per minute, titrated to achieve the desired effect. In refractory cases, the use of a cardiac pacemaker should be considered.

**Heart Block (second and third degree).** Transvenous cardiac pacing.

**Hypotension.** Severe hypotension should respond to a sympathomimetic amine, such as isoprenaline or noradrenaline. In refractory cases, the use of glucagon hydrochloride should be considered.

**Torsade de Pointes.** Direct current (DC) cardioversion, transvenous cardiac pacing, adrenaline (epinephrine), and/or intravenous magnesium sulphate.

**Dialysis.** Dialysis lowers the plasma sotalol concentration by approximately 20%.

**Bronchospasm.** A beta-2-agonist and/or aminophylline.

For information on the management of overdosage, contact the Poisons Information Centre on 13 11 26 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

**Mechanism of Action**

Sotalol is a non-selective beta-adrenoreceptor antagonist without sympathomimetic activity or membrane stabilising activity. It causes a decrease in heart rate and a limited reduction in the force of contraction of the heart. There is a reduction in cardiac work and in myocardial oxygen demand. Sotalol does not decrease blood pressure in normotensive subjects.

Sotalol also possesses Class III antiarrhythmic activity. Sotalol has no known effect on the upstroke velocity of the action potential and therefore no known effect on the depolarisation phase. Its major effects are prolongation of the atrial, ventricular and accessory pathway effective refractory periods. The effect on the ventricular myocardium may be reflected by a lengthening of the QTc interval on electrocardiographic recordings.

Like most other beta-blockers, sotalol inhibits renin release. This suppressive effect is significant both at rest and during exercise.

**Clinical Trials**

No data available.

5.2 PHARMACOKINETIC PROPERTIES

**Absorption**

Sotalol is well absorbed from the gastrointestinal tract. Peak plasma concentrations of 1.4 to 1.7 mg/L are reached at 2 to 3 hours after a 160 mg oral dose.
Distribution
Total apparent volume of distribution of sotalol ranges from 1.6 to 2.4 L/kg. The volume of distribution at steady state is approximately halved in the elderly.

Metabolism
Sotalol is not metabolised by the liver and does not undergo biotransformation (no first-pass effect). There is a positive correlation between sotalol dose and plasma concentration.

Excretion
Sotalol is excreted by glomerular filtration and to a small degree by tubular secretion. After oral administration, about 75% of the dose is excreted in the urine within 72 hours as unchanged sotalol. Less than 10% is excreted in the faeces. The mean elimination half-life of sotalol is $12.7 \pm 1.6$ (SE) hours.

Protein Binding
Sotalol does not bind to plasma proteins and does not significantly cross the blood-brain barrier. However, it is excreted in breast milk and may cross the placental barrier.

Bioavailability
The absolute bioavailability on oral administration is close to 100%. The bioavailability is decreased when sotalol is administered with food, especially milk.

Clinical Implications of Pharmacokinetic Data
As sotalol is primarily excreted by the kidneys, dosage adjustment is necessary in patients with moderate renal impairment. Severe renal impairment (creatinine clearance <10 mL/min) is a contraindication.

5.3 PRECLINICAL SAFETY DATA
Genotoxicity
No data available.

Carcinogenicity
No data available.

6 PHARMACEUTICAL PARTICULARS
6.1 LIST OF EXCIPIENTS
CARDOL tablets also contain the following inactive ingredients: calcium hydrogen phosphate, maize starch, povidone, sodium starch glycollate, purified talc, magnesium stearate.

6.2 INCOMPATIBILITIES
Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 SHELF LIFE
In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE
Store below 30°C.

6.5 NATURE AND CONTENTS OF CONTAINER
Container type: HDPE bottle with a PP child resistant closure.
Pack size: 60 tablets.
Australian Register of Therapeutic Goods (ARTG)
AUST R 43241– CARDOL sotalol hydrochloride 160mg tablet bottle

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL
In Australia, any unused medicine or waste material should be disposed of by taking it to your local pharmacy.

6.7 PHYSICOCHEMICAL PROPERTIES
Sotalol is a white crystalline solid. It is soluble in water (50% w/v) and has a melting point of 210°C.

Chemical Structure

Chemical Name
4’-(2-isopropylamino-1-hydroxy-ethyl)-methanesulfonanilide hydrochloride

Molecular formula
C_{12}H_{20}N_2O_3S·HCl

Molecular weight
303.83

CAS Number
CAS Registry no. 959-24-0

7 MEDICINE SCHEDULE (POISONS STANDARD)
S4 (Prescription Only Medicine)

8 SPONSOR
Alphapharm Pty Ltd trading as Viatris
Level 1, 30 The Bond
30 – 34 Hickson Road
Millers Point NSW 2000
www.viatris.com.au
Phone: 1800 274 276

9 DATE OF FIRST APPROVAL
04/02/1993

10 DATE OF REVISION
10/03/2023
## Summary Table of Changes

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of New Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>Minor editorial changes</td>
</tr>
<tr>
<td>4.3</td>
<td>Addition of contraindications</td>
</tr>
<tr>
<td>4.4</td>
<td>Addition of precautions and warnings</td>
</tr>
<tr>
<td>4.5</td>
<td>Addition of interactions</td>
</tr>
<tr>
<td>4.6 &amp; 4.7</td>
<td>Addition of precautions</td>
</tr>
<tr>
<td>4.8</td>
<td>Addition of adverse effects</td>
</tr>
<tr>
<td>6.5</td>
<td>Correct container closure</td>
</tr>
<tr>
<td></td>
<td>Insert AUST R numbers</td>
</tr>
<tr>
<td>8</td>
<td>Update sponsor details</td>
</tr>
</tbody>
</table>

CARDOL® is a Viatris company trade mark

CARDOL™ Mar 23/01 (CCDS 8-Jun-2020)